Skip to main content
Premium Trial:

Request an Annual Quote

Systems Imagination, Cofactor Genomics Ink Drug Development Services Deal

NEW YORK (GenomeWeb) – Systems Imagination (SII) announced today that it has partnered with Cofactor Genomics to offer services that combine their respective analytical research technologies and expertise for use in drug development.

Under the terms of the deal, the partners will join Cofactor's RNA-seq know-how with SII's big data analytics offerings. The resulting services, SII said, will help pharmaceutical research clients better understand and predict patient drug responses, identify disease targets, and develop combination therapies.

"Our clients have been asking us to help them analyze data from ever more powerful molecular technologies like RNA-seq," SII CEO Chris Yoo said in a statement. "By partnering with Cofactor, we can provide our customers with best-of-breed analytical research services that can generate the highest quality data required in performing translational studies of disease."

Cofactor CSO Jon Armstrong added, "Our partnership will allow researchers to extract valuable RNA insight that is only attainable with custom analysis solutions."

In February, Cofactor announced its acquisition of Narus Biotechnologies. The firm said the buy would help it to further expand into the realm of RNA diagnostics, and to develop its plans to create RNA-based tests for cancer and neurodegenerative diseases.